First Quadrant’s BioSpecifics Technologies Corp. BSTC Stock Holding History

First Quadrant’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,466	Closed	-$147K	–	712
2019 Q2	$147K	Hold	2,466	–	–	0.01%	546
2019 Q1	$154K	Hold	2,466	–	–	0.01%	533
2018 Q4	$149K	Hold	2,466	–	–	0.01%	584
2018 Q3	$144K	Hold	2,466	–	–	﹤0.01%	664
2018 Q2	$111K	Sell	2,466 -4,249	-63%	-$183K	﹤0.01%	644
2018 Q1	$298K	Sell	6,715 -4,916	-42%	-$206K	0.01%	576
2017 Q4	$504K	Buy	11,631 +4,015	+53%	+$180K	0.01%	538
2017 Q3	$354K	Sell	7,616 -1,601	-17%	-$76.7K	0.01%	617
2017 Q2	$456K	Sell	9,217 -22,233	-71%	-$1.16M	0.01%	551
2017 Q1	$1.72M	Sell	31,450 -2,327	-7%	-$123K	0.03%	387
2016 Q4	$1.88M	Buy	33,777 +17,617	+109%	+$847K	0.04%	359
2016 Q3	$738K	Buy	16,160 +14,660	+977%	+$589K	0.02%	483
2016 Q2	$60K	Hold	1,500	–	–	﹤0.01%	696
2016 Q1	$52K	Hold	1,500	–	–	﹤0.01%	688
2015 Q4	$64K	Buy	1,500 +800	+114%	+$40.1K	﹤0.01%	649
2015 Q3	$30K	Buy	+700	New	+$37.8K	﹤0.01%	717

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

First Quadrant's BSTC Position: Q3 2019 in Review

First Quadrant sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2019, closing a stake of 2,466 shares — an estimated $147K sold.

First Quadrant first reported a position in BSTC in Q3 2015 and held it in 16 quarters. The position peaked at $1.88M in Q4 2016. 114 funds tracked by Wall St. Rank hold BSTC as of Q3 2019.

First Quadrant reported no remaining BioSpecifics Technologies Corp. position as of Q3 2019 after selling out during the quarter.
First Quadrant sold 2,466 BioSpecifics Technologies Corp. shares in Q3 2019, an estimated $147K.
First Quadrant first reported a position in BioSpecifics Technologies Corp. in Q3 2015 and held it in 16 quarters.
First Quadrant's BioSpecifics Technologies Corp. position peaked at $1.88M in Q4 2016.
114 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2019.

Based on First Quadrant's 13F filing for Q3 2019, filed 25 Oct 2019.